Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

You may also be interested in...



Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

Both antidepressants are not needed on Part D drug formularies “since escitalopram is the component of citalopram that is responsible for the antidepressant effects,” CMS says. Iressa and Cerebyx may also be left off formularies despite the requirement that “all or substantially all” drugs in their categories be included.

Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

Both antidepressants are not needed on Part D drug formularies “since escitalopram is the component of citalopram that is responsible for the antidepressant effects,” CMS says. Iressa and Cerebyx may also be left off formularies despite the requirement that “all or substantially all” drugs in their categories be included.

Ovations Chooses Walgreens PBM To Administer Medicare Part D Plan

The health plan says its choice of Walgreens reflects the consumer-based focus of the Part D market. Ovations parent company UnitedHealth Group is Medco's largest health plan client and continues to have a strong relationship with Medco with respect to the group-based business, Ovations says.

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel